BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology. Its products include a treatment for snakebites, antidotes to treat toxicity associated with medicines used for heart conditions and cancer, and interventional oncology products that are used to treat patients with liver or prostate tumours. Its focus within Specialty Pharmaceuticals is on antidote products that are used within hospitals. Its interventional medicine products are embolisation and drug-eluting beads used primarily to treat patients with liver tumours and brachytherapy products used mainly for early-stage prostate cancer. Licensing & Biotechnology business area consists of licensed products and programmes and generates royalties for BTG. Its commercial sold products include CroFab (crotalidae polyvalent immune fab (ovine)) and DigiFab (digoxin immune fab (ovine)).